Phenylephrine in Spinal Anesthesia in Preeclamptic Patients
Information source: Northwestern University
Information obtained from ClinicalTrials.gov on February 12, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Preeclampsia; Spinal Anesthesia; Hypotension; Cesarean Section
Intervention: Ephedrine (Drug); Phenylephrine (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Northwestern University Official(s) and/or principal investigator(s): Cynthia A. Wong, M.D., Principal Investigator, Affiliation: Northwestern University
Summary
Hypotension remains a common clinical problem after induction of spinal anesthesia for
cesarean delivery. Maternal hypotension has been associated with considerable morbidity
(maternal nausea and vomiting and fetal/neonatal acidemia). Traditionally, ephedrine has been
the vasopressor of choice because of concerns about phenylephrine's potential adverse effect
on uterine blood flow. This practice was based on animal studies which showed that ephedrine
maintained cardiac output and uterine blood flow, while direct acting vasocontrictors, e. g.,
phenylephrine, decreased uteroplacental perfusion. However, several recent studies have
demonstrated that phenylephrine has similar efficacy to ephedrine for preventing and treating
hypotension and may be associated with a lower incidence of fetal acidosis. All of these
studies have been performed in healthy patients undergoing elective cesarean delivery.
Preeclampsia complicates 5-6% of all pregnancies and is a significant contributor to maternal
and fetal morbidity and mortality. Many preeclamptic patients require cesarean delivery of
the infant. These patients often have uteroplacental insufficiency. Given the potential for
significant hypotension after spinal anesthesia and its effect on an already compromised
fetus, prevention of (relative) hypotension in preeclamptic patients is important. Spinal
anesthesia in preeclamptic patients has been shown to have no adverse neonatal outcomes as
compared to epidural anesthesia when hypotension is treated adequately. Due to problems
related to management of the difficult airway and coagulopathy, both of which are more common
in preeclamptic women, spinal anesthesia may be the preferred regional anesthesia technique.
Recent studies have demonstrated that preeclamptic patients may experience less hypotension
after spinal anesthesia than their healthy counterparts. To our knowledge, phenylephrine for
the treatment of spinal anesthesia-induced hypotension has not been studied in women with
preeclampsia. The aim of our study is to compare intravenous infusion regimens of
phenylephrine versus ephedrine for the treatment of spinal anesthesia induced hypotension in
preeclamptic patients undergoing cesarean delivery. The primary outcome variable is umbilical
artery pH.
Clinical Details
Official title: Phenylephrine Versus Ephedrine to Treat Spinal Anesthesia-Induced Hypotension in Preeclamptic Patients During Cesarean Delivery
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: The umbilical artery pH in the phenylephrine group will be higher than in the ephedrine group, although the overall incidence of absolute fetal acidosis is not anticipated to be different between groups.
Secondary outcome: Efficacy of study drug in preventing and treating hypotension associated with spinal anesthesia in women with preeclampsia
Detailed description:
The study will be approved by the Northwestern University Institutional Review Board.
Eligible women admitted to the Labor and Delivery Unit of Prentice Women's Hospital will be
approached for study participation immediately after the routine preanesthetic evaluation.
This usually occurs shortly after admission to the Labor and Delivery Unit. Women who agree
to participate will give written, informed consent at this time.
Preparation and initiation of spinal anesthesia will proceed according to routine practice at
our institution. A 16-gauge IV catheter will be inserted under local anesthesia in the
pre-operative labor and delivery suite. An IV infusion of lactated Ringer's solution will be
started at a minimal rate to maintain vein patency. Patients will be premedicated with
metoclopramide 10 mg and ranitidine 50 mg IV at least 30 minutes prior to procedure for
aspiration prophylaxis. Patients will be allowed to rest undisturbed for several minutes in
the left lateral tilt position, during which heart rate (HR) and systolic blood pressure
(SBP) will be taken every 1-2 minutes for at least 3 measurements. Baseline HR and SBP will
be the mean of these three recordings.
The subjects will be randomized according to a computer-generated randomization table to one
of two groups: Group 1 will receive a phenylephrine infusion and Group 2 will receive an
ephedrine infusion. All study medications will be prepared by an investigator not involved in
the care of the patient or collection of data. Both the anesthesiologist managing the
patient's anesthetic, as well as the patient, will be blinded to the study medication.
Upon arrival to the operating room, 30 mL of 0. 3 M sodium citrate will be given orally and
standard monitoring will performed, including non-invasive BP, electrocardiography and pulse
oximetry. Oxygen will be given at 3 liter per minute by nasal cannula. Fetal heart rate will
be monitored by external cardiotocography until the time of surgical preparation. 500 mL of
lactated Ringer's solution will be given as a bolus concurrently with the start of the spinal
anesthesia procedure. Spinal anesthesia will be induced with patients in the sitting
position. After sterile skin preparation and draping, the skin will be infiltrated with
lidocaine, a 25 gauge Whitacre needle will be inserted at the L3-L4 vertebral interspace (±
one vertebral interspace) and bupivacaine 0. 75%, 1. 6 mL (12 mg), fentanyl 15 μg and morphine
150 μg will be injected intrathecally. Patients will be immediately placed supine with left
uterine displacement. SBP will be measured every 1 minute beginning 1 minute after spinal
injection for 10 minutes, then every 2. 5 minutes for the remainder of the procedure.
Patients' hemodynamic data will be recorded throughout the procedure and printed at the end
of the surgery. Five minutes after spinal injection, the sensory level of anesthesia will be
assessed by loss of pinprick discrimination using von Frey hairs. If the patient fails to
obtain at least a T6 sensory level of anesthesia, that patient will be withdrawn from the
study. Preincision antibiotics, magnesium sulfate and uterotonic agents will be administered
intraoperatively per routine practice.
An unblinded investigator will prepare solutions of phenylephrine 100 μg per mL and ephedrine
8000 μg per mL (potency phenylephrine: ephedrine 80: 111). The investigator will place 20 mL of
the study medication into a syringe which will be given to the managing anesthesiologist for
infusion via a syringe pump. The infusion will be attached to the IV cannula at the most
distal. The infusion will be initiated immediately after completion of the spinal injection
at a rate of 1 mL per minute and continued for a minimum of two minutes after which the
infusion will either be stopped, continued or increased based on the SBP measurement each
minute. The goal will be to maintain SBP ≥ 80% baseline, but not > 160 mmHg. After each
measurement of SBP, the infusion will be stopped if the SBP is greater than 80% baseline SBP,
and the infusion will be continued or restarted if the SBP is approximately equal to 80%
baseline SBP. 12 The infusion will be increased by 1 mL per minute if the SBP measurement is
less than 80% baseline. For the purpose of this study, we will define hypotension as a
decrease in SBP to < 80% of baseline. 13 Each time there is a SBP measurement demonstrating
hypotension as defined above, the patient will receive a 1 mL IV bolus of the study solution
via the infusion pump and the infusion will be increased by 1 mL per minute. The infusion and
bolus protocol will be continued until delivery, after which further management will be at
the discretion of the managing anesthesiologist to maintain SBP. If the baseline SBP > 160
mmHg, the infusion will not be started until the SBP decreases to 160 mmHg. Infusion
management will then proceed as described above.
The total volumes of the study solutions given by infusion and bolus up to the time delivery
will be recorded. Bradycardia (defined as HR < 60 bpm) associated with an SBP equal or
greater to baseline SBP will be treated by stopping the study solution and bradycardia
associated with SBP < 80% baseline will be treated with atropine intravenously. Hypotension
unresponsive to study medication will be treated with epinephrine (10 μg/mL) intravenous
boluses (1 mL) until correction of hypotension. Nausea or vomiting not associated with
hypotension will be treated with ondansetron 4 mg IV.
After delivery, oxytocin 10-20 IU will be given by slow IV infusion per routine. The infant's
1 and 5 minute Apgar scores will be assessed by the nurse or pediatrician blinded to patient
group. The results of routine umbilical cord blood gas analysis will be recorded.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- ASA PS II - III women 18 years old and older with singleton pregnancies scheduled for
cesarean delivery (no trial of labor) under spinal anesthesia with a diagnosis of
preeclampsia (see criteria above) will be eligible for inclusion in the study.
Exclusion Criteria:
- Patients with failed trial of labor, with preexisting hypertension, body mass index ≥
40 kg/m2, resting heart rate < 60 bpm, progression to eclampsia, multiple gestation
pregnancy, known fetal anomalies, contraindications to spinal anesthesia,
participation in another investigational study, emergency procedure or refusal of
consent will be excluded.
- Patients that fail to achieve a T6 level of anesthesia to pinprick sensation or
require conversion to general anesthesia will be withdrawn from the investigation.
Locations and Contacts
Northwestern University, Chicago, Illinois 60611, United States; Recruiting Robert McCarthy, PharmD, Phone: 312-926-9015, Email: r-mccarthy@northwestern.edu Cynthia A. Wong, M.D., Principal Investigator
Northwestern Memorial Hospital, Chicago, Illinois 60611, United States; Recruiting Robert McCarthy, PharmD, Phone: 312-926-9015, Email: r-mccarthy@northwestern.edu Cynthia A Wong, M.D., Principal Investigator
Additional Information
Related publications: Rout CC, Rocke DA. Prevention of hypotension following spinal anesthesia for cesarean section. Int Anesthesiol Clin. 1994 Spring;32(2):117-35. Review. No abstract available. Ayorinde BT, Buczkowski P, Brown J, Shah J, Buggy DJ. Evaluation of pre-emptive intramuscular phenylephrine and ephedrine for reduction of spinal anaesthesia-induced hypotension during Caesarean section. Br J Anaesth. 2001 Mar;86(3):372-6. Lee A, Ngan Kee WD, Gin T. A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. Anesth Analg. 2002 Apr;94(4):920-6, table of contents. Cooper DW, Carpenter M, Mowbray P, Desira WR, Ryall DM, Kokri MS. Fetal and maternal effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology. 2002 Dec;97(6):1582-90. Ngan Kee WD, Khaw KS, Ng FF, Lee BB. Prophylactic phenylephrine infusion for preventing hypotension during spinal anesthesia for cesarean delivery. Anesth Analg. 2004 Mar;98(3):815-21, table of contents. Nelson-Piercy C, James PR. Management of hypertension before, during, and after pregnancy. Heart 2004;90:1499-1504. [No authors listed] Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000 Jul;183(1):S1-S22. Visalyaputra S, Rodanant O, Somboonviboon W, Tantivitayatan K, Thienthong S, Saengchote W. Spinal versus epidural anesthesia for cesarean delivery in severe preeclampsia: a prospective randomized, multicenter study. Anesth Analg. 2005 Sep;101(3):862-8, table of contents. Aya AG, Mangin R, Vialles N, Ferrer JM, Robert C, Ripart J, de La Coussaye JE. Patients with severe preeclampsia experience less hypotension during spinal anesthesia for elective cesarean delivery than healthy parturients: a prospective cohort comparison. Anesth Analg. 2003 Sep;97(3):867-72. Aya AG, Vialles N, Tanoubi I, Mangin R, Ferrer JM, Robert C, Ripart J, de La Coussaye JE. Spinal anesthesia-induced hypotension: a risk comparison between patients with severe preeclampsia and healthy women undergoing preterm cesarean delivery. Anesth Analg. 2005 Sep;101(3):869-75, table of contents. Saravanan S, Kocarev M, Wilson RC, Watkins E, Columb MO, Lyons G. Equivalent dose of ephedrine and phenylephrine in the prevention of post-spinal hypotension in Caesarean section. Br J Anaesth. 2006 Jan;96(1):95-9. Epub 2005 Nov 25. Kee WD, Khaw KS, Ng FF. Prevention of hypotension during spinal anesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. Anesthesiology. 2005 Oct;103(4):744-50. Ngan Kee WD, Khaw KS, Ng FF. Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. Br J Anaesth. 2004 Apr;92(4):469-74. Epub 2004 Feb 20.
Starting date: July 2006
Ending date: December 2010
Last updated: November 25, 2008
|